Immunome’s (IMNM) “Outperform” Rating Reaffirmed at Wedbush

Immunome (NASDAQ:IMNM)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a research note issued to investors on Monday,RTT News reports. They presently have a $33.00 price target on the stock. Wedbush’s price target would suggest a potential upside of 278.01% from the stock’s previous close.

Separately, Piper Sandler cut their target price on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $27.17.

Immunome Stock Performance

IMNM opened at $8.73 on Monday. The stock has a market capitalization of $696.45 million, a price-to-earnings ratio of -1.08 and a beta of 1.93. The company has a fifty day moving average of $10.09 and a 200 day moving average of $11.89. Immunome has a fifty-two week low of $8.39 and a fifty-two week high of $26.70.

Insider Buying and Selling at Immunome

In other Immunome news, CEO Clay B. Siegall acquired 150,000 shares of the stock in a transaction on Friday, January 31st. The stock was acquired at an average price of $7.75 per share, for a total transaction of $1,162,500.00. Following the completion of the transaction, the chief executive officer now directly owns 669,636 shares of the company’s stock, valued at $5,189,679. This trade represents a 28.87 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 8.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Immunome

Several institutional investors have recently bought and sold shares of IMNM. Victory Capital Management Inc. lifted its position in Immunome by 48.1% during the third quarter. Victory Capital Management Inc. now owns 730,785 shares of the company’s stock valued at $10,684,000 after purchasing an additional 237,497 shares during the last quarter. Intech Investment Management LLC bought a new stake in shares of Immunome in the 3rd quarter worth about $219,000. Primecap Management Co. CA lifted its holdings in shares of Immunome by 4.5% in the 3rd quarter. Primecap Management Co. CA now owns 280,800 shares of the company’s stock worth $4,105,000 after acquiring an additional 12,000 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Immunome by 217.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company’s stock worth $6,469,000 after acquiring an additional 302,916 shares during the last quarter. Finally, Cerity Partners LLC lifted its holdings in shares of Immunome by 10.5% in the 3rd quarter. Cerity Partners LLC now owns 53,103 shares of the company’s stock worth $776,000 after acquiring an additional 5,043 shares during the last quarter. Institutional investors own 44.58% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.